Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	9.24B
Revenue (ttm)	1.18B
Net Income (ttm)	315.02M
Shares Out	393.77M
EPS (ttm)	0.79
PE Ratio	29.73
Forward PE	26.83
Dividend	0.15 (0.64%)
Ex-Dividend Date	May 30, 2024

Volume	9,023,906
Average Volume	12,895,885
Open	26.70
Previous Close	23.35
Day's Range	23.28 - 24.20
52-Week Range	17.20 - 28.79
Beta	0.80
RSI	48.68
Earnings Date	Apr 22, 2025

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, sele...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,119
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2023, Amoy Diagnostics's revenue was 1.04 billion, an increase of 23.91% compared to the previous year's 842.18 million. Earnings were 261.48 million, a decrease of -0.86%.